Previous 10 | Next 10 |
Karyopharm Therapeutics (NASDAQ: KPTI ) reports positive top-line results from the Phase 2b SADAL (Selinexor Against Diffuse Aggressive Lymphoma) study evaluating selinexor, an, oral Selective Inhibitor of Nuclear Export (SINE) compound, in patients with relapsed or refractory diffuse larg...
-- 29.6% Overall Response Rate Including 9.6% Complete Response Rate -- -- Amongst the Patients with Complete or Partial Response, Median Duration of Response was 9.2 Months and Median Overall Survival was 29.7 months -- -- Company Plans to Submit New Drug Ap...
NEWTON, Mass., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to selinexor, the Company’s first-in-class, oral S...
NEWTON, Mass., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief Executive Officer, will present at the Jefferies 2018 London Healthcare Conference on Wednesday, Novemb...
Ceremony to Commemorate Five-Year Listing Anniversary NEWTON, Mass., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that company executives, including founder Sharon Shacham PhD, MBA, President and ...
NEWTON, Mass., Nov. 02, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 127,500 shares o...
-- Top-line Results from Phase 2b SADAL Study in DLBCL to be Presented -- -- Additional Results from the Pivotal Phase 2b STORM Study in Penta-Refractory Multiple Myeloma and Updated Phase 1b/2 STOMP Data in Relapsed or Refractory Multiple Myeloma to be Highlighted in ...
We've turned the page to November, and investors across the globe may feel a bit of unconscious relief. Stock markets do fluctuate, but months like October are never fun. And that has been especially acute in biotech. Leading ETFs like IBB and XBI dropped ~15% and 18% respectively in October...
-- Conference Call Scheduled for Thursday, November 8, 2018 at 8:30 a.m. ET -- NEWTON, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that it will report third quarter 2018 financi...
Please note that I am affiliated with Avisol Capital Partners and their Total Pharma Tracker service. They have also covered the companies in this article in their writings, and I wanted to make readers aware of the potential for overlapping coverage. Genmab ( GNMSF ) and their par...
News, Short Squeeze, Breakout and More Instantly...
Karyopharm Therapeutics Inc. Company Name:
KPTI Stock Symbol:
NASDAQ Market:
Karyopharm Therapeutics Inc. Website:
2024-08-06 22:30:18 ET Image source: The Motley Fool. Karyopharm Therapeutics (NASDAQ: KPTI) Q2 2024 Earnings Call Aug 06, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Karyopharm Therapeutics (KPTI) Q2 2024 Earnings C...
Karyopharm Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress PR Newswire – Achieves Second Quarter 2024 Total Revenue of $42.8 Million and U.S. XPOVIO® (selinexor) Net Product Revenue of $28.0 Million ; Positive Momentum e...
Karyopharm to Report Second Quarter 2024 Financial Results on August 6, 2024 PR Newswire -- Conference Call Scheduled for Tuesday, August 6, 2024 , at 8:00 a.m. ET -- NEWTON, Mass. , July 31, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasd...